H
Hookipa Pharma
Hookipa Pharma
About Hookipa Pharma
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of immunotherapeutics. These therapeutics are designed to target infectious diseases and cancers by leveraging the company's proprietary arenavirus platform, which aims to reprogram the immune system to fight these conditions more effectively. The company primarily serves the healthcare sector, including patients, healthcare providers, and research institutions. Operating in the biopharmaceutical market, HOOKIPA's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, grants, and future product sales. The company is headquartered in New York, USA, and Vienna, Austria, and is publicly traded on NASDAQ under the ticker symbol HOOK.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Vienna, Austria
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Hookipa Pharma.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sofinnova Partners
Forbion Capital Partners
BioMedVC
Takeda Ventures
Boehringer Ingelheim Venture Fund
Series B and later7 investors entered at this stage
HBM Partners
Hillhouse Capital- SCSirona Capital
Gilead Sciences
Redmile Group
Samsara BioCapital
Invus
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hookipa Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hookipa Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.